Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759525 · ClinicalTrials.gov registry record · Phase 2
The Role of Mineralocorticoid Receptors in Vascular Function
A Phase 2 study of Apparent Mineralocorticoid Excess (AME), sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00759525 is a Phase 2 study of Apparent Mineralocorticoid Excess (AME) that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00759525, a Phase 2 study of Apparent Mineralocorticoid Excess (AME), has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to figure out how decreasing the activity of 11-beta hydroxysteroid dehydrogenase (11-beta HSD) will affect your blood vessel function. 11-beta HSD, which is found in the kidneys and blood vessels, is a natural protein that when active helps to keep your blood pressure under control.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Glycyrrhetic Acid
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2002-02 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759525
The ClinicalTrials.gov registry entry for NCT00759525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Apparent Mineralocorticoid Excess (AME) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00759525 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00759525 about?
NCT00759525 is a clinical study titled "The Role of Mineralocorticoid Receptors in Vascular Function". The purpose of this study is to figure out how decreasing the activity of 11-beta hydroxysteroid dehydrogenase (11-beta HSD) will affect your blood vessel function. 11-beta HSD, which is found in the kidneys and blood vessels, is a natural protein that when active helps to keep your blood pressure u...
What is the current status of trial NCT00759525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2002-02. Estimated completion is 2009-09.
What conditions does trial NCT00759525 study?
This clinical trial studies the following conditions: Apparent Mineralocorticoid Excess (AME).
What interventions are being tested in trial NCT00759525?
The interventions under investigation include: Placebo (DRUG), Glycyrrhetic Acid (DRUG).
Who is sponsoring clinical trial NCT00759525?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00759525 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.